| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/13/2005 | WO2005003159A1 Complement depletion using recombinant human c3-derivatives |
| 01/13/2005 | WO2005003156A1 Polypeptides having binding affinity for her2 |
| 01/13/2005 | WO2005003153A1 Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof |
| 01/13/2005 | WO2005002617A2 Use of compositions comprising a soluble form of hla-g in the treatment of blood diseases |
| 01/13/2005 | WO2005002615A1 Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| 01/13/2005 | WO2005002614A1 Methods and compositions for treating disorders of the extracellular matrix |
| 01/13/2005 | WO2005002613A1 Pharmaceutical compositions comprising an epitope of platelet gpiiia protein |
| 01/13/2005 | WO2005002605A1 Fish protein hydrolyzate |
| 01/13/2005 | WO2005002604A1 Pharmaceutical active ingredient to combat tumours |
| 01/13/2005 | WO2005002603A1 Agent for preventing and curing pathological states associated with endorphin deficiency in organism |
| 01/13/2005 | WO2005002601A1 Conditioned matrix compositions for tissue restoration |
| 01/13/2005 | WO2005002549A1 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| 01/13/2005 | WO2005002526A2 Method and compositions for treatment of viral infections |
| 01/13/2005 | WO2005002516A2 Leukocyte internalized peptide-drug conjugates |
| 01/13/2005 | WO2005002508A2 Macromolecular platinum chelates |
| 01/13/2005 | WO2005002504A2 Protection against vertical transmission of pathogenic infections |
| 01/13/2005 | WO2005002494A2 Pharmaceutical active ingredient to combat prostatic cancer |
| 01/13/2005 | WO2004094605A8 Methods and compositions for inhibiting stat signaling pathways |
| 01/13/2005 | WO2004086039A3 A method for modulating nod1 activity, use of a mtp related molecule for modulating nod1 activity, and therapeutic applications thereof |
| 01/13/2005 | WO2004082706A3 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders |
| 01/13/2005 | WO2004082568A3 Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) |
| 01/13/2005 | WO2004080375A3 Vaccine therapy of atherosclerosis |
| 01/13/2005 | WO2004077062A3 Method for selecting a candidate drug compound |
| 01/13/2005 | WO2004069136A3 Mucin-like polypeptides |
| 01/13/2005 | WO2004047733B1 Anti-tumor metallocomplexes of crude extract from canavalia ensiformis |
| 01/13/2005 | WO2004044170A3 A pancreatic islet transcription factor and uses thereof |
| 01/13/2005 | WO2004043141A3 Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians |
| 01/13/2005 | WO2004042077A3 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) |
| 01/13/2005 | WO2004031230A3 Novel mhc ii associated peptides |
| 01/13/2005 | WO2004026896A3 Hcv ns-3 serine protease inhibitors |
| 01/13/2005 | WO2004024097A8 Compositions and methods for the treatment of immune related diseases |
| 01/13/2005 | WO2004006958A8 Stable pharmaceutical composition comprising erythropoietin |
| 01/13/2005 | WO2003104273A9 Therapeutic epitopes and uses thereof |
| 01/13/2005 | WO2003096983A3 Method of treating dyslipidemic disorders |
| 01/13/2005 | WO2003089569A3 Use of il-19, il-22 and il-24 to treat hematopoietic disorders |
| 01/13/2005 | WO2003074073A3 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 01/13/2005 | WO2003072715A8 Gasp1: a follistatin domain containing protein |
| 01/13/2005 | WO2003038040A3 32235, a human aminotransferase family member and uses therefor |
| 01/13/2005 | WO2003017943A3 Therapeutic compositions and methods for treating viral infection |
| 01/13/2005 | WO2002092001A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/13/2005 | WO2002061049A3 Novel molecules of the pyrin/nbs/lrr protein family and uses thereof |
| 01/13/2005 | US20050010060 Novel quinones as disease therapies |
| 01/13/2005 | US20050010056 Concentrating aqueous fractions of lisinopril by reverse osmosis |
| 01/13/2005 | US20050010042 Expression vector comprising nucleotide sequences comprising pro-polypeptide for use in the diagnosis, prevention and treatment of cell proliferative, inflammatory, cardiovascuar and nervous system disorders |
| 01/13/2005 | US20050010041 Bacterial gene and method of treating a gram negative bacterial infection |
| 01/13/2005 | US20050010034 Pyrogenic exotoxin type C (SPE-C) protein for use in generating vaccine for use in prevention of streptocccal infection/poisioning |
| 01/13/2005 | US20050010033 Pyrogenic exotoxin type C (SPE-C) protein for use in generating vaccine for use in prevention of streptocccal infection/poisioning |
| 01/13/2005 | US20050009851 Use of cyclopeta[g]quinazoline derivatives for treating cancer |
| 01/13/2005 | US20050009847 Compounds and methods for increasing neurogenesis |
| 01/13/2005 | US20050009816 Potassium channel modulators |
| 01/13/2005 | US20050009807 Preventing the deposits of amyloid protein, treating neurodegenerative disease, Alzheimer's disease and Down's Syndrome; {[carbamoyl]cycloalkyl}-N-(2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))- or (2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))-carboxamide |
| 01/13/2005 | US20050009756 Polymorph of a pharmaceutical |
| 01/13/2005 | US20050009755 (74)(3S)-3-amino-1-(1-benzyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-4-yl)-5-methyl-2-heptanone for example; cysteine protease inhibitors; treating bone resorption diseases such as osteoporosis |
| 01/13/2005 | US20050009753 Oligopeptides containing glutamic acid, proline and one other peptide such as glutamic acid, phenylalanine, lysine, tyrosine or valine |
| 01/13/2005 | US20050009752 Novel peptides and medicinal uses thereof |
| 01/13/2005 | US20050009751 Pentapeptide compounds and uses related thereto |
| 01/13/2005 | US20050009749 Also a gene encoding the protein and a Streptomyces sp. strain producing it; used to treat neurodegenerative disorders like Alzheimer's disease and Down syndrome |
| 01/13/2005 | US20050009748 Compositions for delivering peptide YY and PYY agonists |
| 01/13/2005 | US20050009747 High purity lipopeptides |
| 01/13/2005 | US20050009746 Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
| 01/13/2005 | US20050009745 TSG101 as inhibitor of HIV production |
| 01/13/2005 | US20050009744 Treatment of congestive heart failure |
| 01/13/2005 | US20050009743 Analyzing changes in protein; genetic engineering |
| 01/13/2005 | US20050009742 Compounds and methods for increasing neurogenesis |
| 01/13/2005 | US20050009741 Copolymer made by depolymerizing chitosan and acylating such as with glutaryl and propionyl groups; mixture with peptides such as buserelin, deslorelin, histrelin; ionic conjugate with parathyroid hormone |
| 01/13/2005 | US20050009740 Mixture of carrier, target peptide and immune response triggers |
| 01/13/2005 | US20050009739 Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| 01/13/2005 | US20050009738 Interleukin with nucleic acid carrier |
| 01/13/2005 | US20050009736 Administering by hemodilution an aqueous cell-free polyalkylene oxide surface modified hemoglobin without intramolecular crosslinking; oxygen affinity greater than whole blood; blood disorders |
| 01/13/2005 | US20050009732 Antigrowth agents; anticancer agents; sphingosine kinase |
| 01/13/2005 | US20050009183 Antisense modulation of hypothetical protein LOC51249 expression |
| 01/13/2005 | US20050009178 Matrix comprised of biopolymer fibers for use in propagation and culturing of tissues; tissue engineering and regenerative medicine; tissue grafting; prosthetics |
| 01/13/2005 | US20050009177 Telomerase interference |
| 01/13/2005 | US20050009150 Humanized antibodies that recognize beta amyloid peptide |
| 01/13/2005 | US20050009149 Trimeric tumor necrosis factor receptors for use as modulator for treatment of rheumatoid arthritis, atherosclerosis, osteoporosis, allograft rejection, cancer, inflammatory bowel and autoimmune diseases |
| 01/13/2005 | US20050009147 Parathyroid hormone variants; site-directed mutagenesis; for treatment of bone disorders |
| 01/13/2005 | US20050009145 Mammalian receptor proteins; related reagents and methods |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009141 Epidermal differentiation factor |
| 01/13/2005 | US20050009140 Elongase genes and uses thereof |
| 01/13/2005 | US20050009137 Intracellular estradiol binding protein, a polynucleotide encoding the same and cell lines overexpressing the same |
| 01/13/2005 | US20050009106 Mammalian cytokine; related reagents |
| 01/13/2005 | US20050009089 Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter protein ABC1 |
| 01/13/2005 | US20050009088 Antisense modulation of apolipoprotein B-expression |
| 01/13/2005 | US20050009085 44 Human secreted proteins |
| 01/13/2005 | US20050009073 Polyamide nucleic acid derivatives, and agents, and processes for preparing them |
| 01/13/2005 | US20050009065 Modulators of Nod1 signaling |
| 01/13/2005 | US20050009062 Phosphodiesterase 10 |
| 01/13/2005 | US20050009056 Anti-infective therapy |
| 01/13/2005 | US20050009042 Oligonucleotide seqences for controlling expression of leptin receptor gene associated protein (OB-RGRP); for treatment and prevention of bone, thrombic, sexual, blood, immunological, inflammatory and cancer disorders |
| 01/13/2005 | US20050009041 Peptide nucleic acids and synthetic procedures therefor |
| 01/13/2005 | US20050009025 A soluble T cell receptor for use as diagnostic indicator of infection and autoimmune diseases |
| 01/13/2005 | US20050009023 Using allelic variance in genes associated with neuroadaptation of stress-responsive systems as a diagnostic and prognostic indicators of addiction reward disorders |
| 01/13/2005 | US20050009021 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 01/13/2005 | US20050008688 Oral administering; tablet with enteric coating; supplying drug to gastrointestinal systems |
| 01/13/2005 | US20050008661 Mixture of polymer in solvent; drug delivery; storage stability |
| 01/13/2005 | US20050008658 Enterococcus antigens and vaccines |
| 01/13/2005 | US20050008654 For prevention, therapy of sepsis shock, thrombosis disorders |
| 01/13/2005 | US20050008653 In situ binding of polypeptide to stabilizer; induction apoptosis |
| 01/13/2005 | US20050008645 Antibodies Specific For Phosphatase Subunit of LAR |